Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Thomas E. Yankeelov
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, Thomas E. Yankeelov wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Clinical Trial Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. 2018

Cardin, Dana B / Goff, Laura W / Chan, Emily / Whisenant, Jennifer G / Dan Ayers, G / Takebe, Naoko / Arlinghaus, Lori R / Yankeelov, Thomas E / Berlin, Jordan / Merchant, Nipun. ·Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. dana.cardin@vanderbilt.edu. · Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. dana.cardin@vanderbilt.edu. · Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. · Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. · Amgen Inc., Thousand Oaks, CA, USA. · Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA. · Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. · Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA. · Vanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, USA. · Institute for Computational and Engineering Sciences, Departments of Biomedical Engineering and Diagnostic Medicine, Livestrong Cancer Institutes, University of Texas, Austin, TX, USA. · Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA. ·Invest New Drugs · Pubmed #28990119.

ABSTRACT: Pancreatic adenocarcinoma remains a major therapeutic challenge, as the poor (<8%) 5-year survival rate has not improved over the last three decades. Our previous preclinical data showed cooperative attenuation of pancreatic tumor growth when dasatinib (Src inhibitor) was added to erlotinib (EGFR inhibitor) and gemcitabine. Thus, this study was designed to determine the maximum-tolerated dose of the triplet combination. Standard 3 + 3 dose escalation was used, starting with daily oral doses of 70 mg dasatinib and 100 mg erlotinib with gemcitabine on days 1, 8, and 15 (800 mg/m

2 Clinical Trial Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. 2016

Chan, Emily / Arlinghaus, Lori R / Cardin, Dana B / Goff, Laura / Berlin, Jordan D / Parikh, Alexander / Abramson, Richard G / Yankeelov, Thomas E / Hiebert, Scott / Merchant, Nipun / Bhaskara, Srividya / Chakravarthy, Anuradha Bapsi. ·Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States. · Vanderbilt University Institute of Imaging Science, United States. · Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States; Vanderbilt University Institute of Imaging Science, United States; Departments of Radiology and Radiological Sciences, Biomedical Engineering, Physics, and Cancer Biology, Vanderbilt University, United States. · Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, UHealth - University of Miami Health System, United States. · Department of Radiation Oncology and Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, United States. · Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States. Electronic address: bapsi.chak@vanderbilt.edu. ·Radiother Oncol · Pubmed #27106554.

ABSTRACT: BACKGROUND AND PURPOSE: This single institution phase I trial determined the maximum tolerated dose (MTD) of concurrent vorinostat and capecitabine with radiation in non-metastatic pancreatic cancer. MATERIAL AND METHODS: Twenty-one patients received escalating doses of vorinostat (100-400mg daily) during radiation. Capecitabine was given 1000mg q12 on the days of radiation. Radiation consisted of 30Gy in 10 fractions. Vorinostat dose escalation followed the standard 3+3 design. No dose escalation beyond 400mg vorinostat was planned. Diffusion-weighted (DW)-MRI pre- and post-treatment was used to evaluate in vivo tumor cellularity. RESULTS: The MTD of vorinostat was 400mg. Dose limiting toxicities occurred in one patient each at dose levels 100mg, 300mg, and 400mg: 2 gastrointestinal toxicities and one thrombocytopenia. The most common adverse events were lymphopenia (76%) and nausea (14%). The apparent diffusion coefficient (ADC) increased in most tumors. Nineteen (90%) patients had stable disease, and two (10%) had progressive disease at time of surgery. Eleven patients underwent surgical exploration with four R0 resections and one R1 resection. Median overall survival was 1.1years (95% confidence interval 0.78-1.35). CONCLUSIONS: The combination of vorinostat 400mg daily M-F and capecitabine 1000mg q12 M-F with radiation (30Gy in 10 fractions) was well tolerated with encouraging median overall survival.